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Abstract: We are normally unaware of the complex signalling events which continuously 
occur within our internal organs. Most of us only become cognisant when sensations of 
hunger, fullness, urgency or gas arise. However, for patients with organic and functional 
bowel disorders pain is an unpleasant and often debilitating reminder. Furthermore, chronic 
pain still represents a large unmet need for clinical treatment. Consequently, chronic pain 
has a considerable economic impact on health care systems and the afflicted individuals. In 
order to address this need we must understand how symptoms are generated within the gut, 
the molecular pathways responsible for generating these signals and how this process 
changes in disease states.  
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1. Gastrointestinal Pain 
Pain and discomfort originating from the gastrointestinal tract are common and often debilitating 
complaints of patients with functional and organic gastrointestinal disorders. Functional gastrointestinal 
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disorders are highly prevalent, affecting up to 30% of the population. These disorders lack an 
underlying organic disease that readily explains their symptoms and encapsulate patients with Non 
Cardiac Chest Pain [1,2], Functional Dyspepsia [3–6] and Irritable Bowel Syndrome [7–10]. Organic 
disorders such as Inflammatory Bowel Disease (which includes Crohn’s Disease and Ulcerative Colitis) 
are chronic relapsing and remitting inflammatory disorders of the gastrointestinal tract affecting  
~3.6 million people in the USA and Europe alone [11–14]. Although the aetiology of these diseases are 
very different, visceral pain is the unifying link and more often than not the most poorly  
managed symptom.  
In the periphery activation of sensory nerve endings, which feed into nociceptive pathways of the 
central nervous system (CNS), give rise to the sensation of pain. The threshold for pain has to be high 
enough not to interfere with normal physiology but low enough that it can be evoked before marked 
tissue damage occurs [15]. In order to achieve this function “nociceptive” nerve endings express a 
variety of ion channels and receptors which transduce mechanical and chemical stimuli or regulate 
neuronal excitability [16–21]. Acute “physiological” pain arising from the gastrointestinal tract 
normally serves as an alarm system that is activated in response to excessive distension or intense 
muscular contractions to warn of impending damage. Unlike acute pain, inflammatory pain is caused 
by injury, irritation or infection and acts as a warning to prevent further damage. Frequent,  
re-occurring “chronic” pain often manifests from an underlying disease [22] and a failure of 
nociceptors to “reset”. Typically, reduced sensory thresholds and increased afferent responsiveness to 
mechanical stimuli underlie pain signalling in a variety of gut based inflammatory and chronic pain 
syndromes [23]. It is becoming clear that the mechanisms underlying acute, inflammatory and chronic 
pain are varied but originate from changes at the level of the periphery [24–28]. Despite a growing list 
of ion channels responsible for signalling acute “physiological” pain we are only beginning to 
determine the channels responsible for inflammatory and chronic visceral pain in animal models and 
translating these findings to human diseases. This article will review very recent advances in this field 
which have brought specific ion channels into the spotlight for pain originating from the gut. 
2. Sensory Afferents Innervating the Gastrointestinal Tract 
Visceral sensory nerves follow three main anatomical pathways from the gastrointestinal tract to the 
CNS - the vagal, splanchnic and pelvic nerves [20]. Vagal afferent fibres have neuronal cell bodies in 
the nodose and jugular ganglia. Splanchnic and pelvic fibres have cell bodies in either the spinal 
thoracolumbar and lumbosacral dorsal root ganglia (DRG) [17,20,29]. Correspondingly, vagal and 
spinal afferent neurons project centrally to either the brainstem or spinal cord respectively. The 
peripheral projections of these neurons terminate at various levels within the gut wall, including the 
mucosa, enteric ganglia, muscle layers, serosa and mesenteric attachments [17,29].  
A wide assortment of afferents have been recorded and described from throughout the entire length 
of the gut, with numerous experimental techniques and mechanical stimuli used to classify their 
function. Historically fibres have been classified by a low- or high-threshold of activation to organ 
distension [30], however, not all fibres respond to distension or can be adequately classified based on 
this stimulus alone [31–34]. In the mouse gastrointestinal tract the picture is somewhat clearer, with 
afferent endings classified into five subtypes according to their functional responsiveness to select 




stimuli and the proposed location of their mechanoreceptive fields [31,34] (Figure 1). These classes are 
termed mucosal, muscular (or tension receptor in the upper gut), muscular/mucosal, serosal and 
mesenteric afferents (Figure 1) [31,34–37]. Mucosal afferents respond to fine tactile stimulation of the 
luminal (mucosal) surface and anatomically appear as bare endings in the lamina propria of villi [38]. 
Muscular afferents (or tension receptors) respond to distension at physiological levels (<20 mmHg or 
low intensity stretch stimuli <3 g; Figure 1) [34,37] and consist of specialized terminals which 
surround myenteric ganglia termed Intraganglionic Laminar Endings (IGLEs) [39–42]. The 
responsiveness of vagal tension receptors quickly saturates at around ~20 mmHg, whilst spinal 
muscular afferents respond linearly over wide-distension pressures (10–60 mmHg) [36,37,43,44]. In 
the colon muscular afferents are prevalent in the pelvic pathway but rare in the splanchnic pathway 
[31,40]. Muscular/mucosal afferents are exclusive to the pelvic pathway and respond to both tactile 
and distension stimuli (Figure 1), but their anatomy is yet to be demonstrated [31]. Serosal and 
mesenteric afferents respond at noxious levels of distension (>35 mmHg) [31,45,46] or higher intensity 
circular stretch (>7 g; Figure 1) [36,37] and in other species correspond with varicose branching axons 
which surround blood vessels [47]. A separate mechanically-insensitive class of fibre has also been 
described which respond only to chemical stimuli [48,49].  
3. What Is a Gut-Innervating Nociceptor? 
This may seem an obvious question, but gut afferent nomenclature and function remain contentious 
issues. In part, this is due to the historical lack of a standardised nomenclature system for defining 
subtypes. Unlike cutaneous afferents, which are classed on nerve fibre conduction velocity and distinct 
response properties [50], the majority of gut afferents have conduction velocities in the C-fibre range (<1 
m/s) [35,36,51–53] and therefore cannot be segregated on this parameter alone. As such defining gut 
afferent subtypes based on mechanical responsiveness to select stimuli (see above) has allowed 
progress in this area. Despite these recent classifications there is still great debate as to which afferent 
subtypes signal “nociceptive” events within the gut. 
Vagal afferents are generally associated with signaling physiological events rather than painful 
events, although there are exceptions notably in the oesophagus [54], whereas spinal pathways are 
generally associated with sensations of pain, bloating, discomfort and urgency [20]. Of the spinal 
afferents the most obvious nociceptive suspects are the high-threshold (serosal and mesenteric) 
afferents as they are activated at distension pressures (threshold ~35 mmHg) [36,37] that are reportedly 
at the start of the noxious range [55]. However, it has also been suggested that low-threshold (muscular 
and muscular/mucosal) afferents can also signal pain, as although they signal physiological events they 
can also encode into the nociceptive range [30,55].  
Despite the apparent controversy surrounding the identity of gut innervating nociceptors, one might 
suggest that effective therapies for visceral pain should preferentially target the higher-threshold 
subtypes of afferent. This would be potentially advantageous, allowing specific targeting of events 
signalled at noxious levels. Although low-threshold afferents can encode into the noxious range one 
would suspect that targeting these afferents would also affect their responsiveness to lower intensity 
events and therefore adversely affect normal perception and reflex function. 




Figure 1. Five classes of mechanosensitive afferent innervate the murine gut.  
(A). Afferents are classified by their responsiveness to distinct mechanical stimuli, circular 
stretch, fine mucosal stroking and focal compression with calibrated von Frey hairs (vfh): 
(A i) Mesenteric and (A ii) serosal afferents respond in a graded manner to focal 
compression with probes and high intensity stretch (≥7 g; see (B ii)) or distension (>35 
mmHg; not shown). They do not respond to low intensity mucosal stroking (10 mg; see A 
(B ii)) or low intensity circular stretch (≤5  g; also see (B ii)); (B iii). Muscular afferents (or 
tension sensitive afferents as they are called in the upper gut) respond to low intensity 
circular stretch (<3 g; also see (B i)) but not fine mucosal stroking; (B iv). Mucosal 
afferents have the lowest mechanical activation thresholds of all afferent classes, 
responding to fine mucosal stroking (10 mg von Frey hair), but do not respond to circular 
stretch; (B v). Muscular/mucosal afferents display the properties of muscular and mucosal 
afferents as they respond to both low intensity stretch and fine mucosal stroking. Overall, 
muscular, mucosal and muscular/mucosal afferents have low-thresholds for mechanical 
activation via stretch or stroking respectively, whilst serosal and mesenteric afferents have 
high-thresholds for mechanical activation by stretch; (C). Graphical representation of the 5 
different subtypes of afferent innervating the mouse colorectum. (A) Modified from 
Brierley et al. [31] with permission; (B) Modified from Hughes et al. [37] with permission; 
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4. Visceral Hypersensitivity 
Visceral hypersensitivity is apparent in numerous Functional Gastrointestinal Disorders [23]. As 
such, investigators have used varying visceral pain models to try and mimic these diseases in an effort 
to determine which afferent subtypes are altered [56]. Most of the controversy centres on the colonic 
pathways and although there is consensus that inflammation does change afferent function there are 
discrepancies in the specific details. These studies show absent or inconsistent effects of inflammation 
on low-threshold distension-sensitive afferents [57–59]. However, in the mouse colon and rectum the 
picture is somewhat clearer with distinct afferent subtypes and pathways involved over different time-
courses [21,37].  
Inflammatory hypersensitivity of splanchnic afferents with high mechanosensory thresholds (serosal 
and mesenteric) but not those with low-thresholds (mucosal and muscular) (Figure 2). Furthermore, the 
extent of this hypersensitivity is greater after recovery from overt tissue inflammation [21,37]. Pelvic 
afferents are not hypersensitive during acute inflammation, however, pelvic serosal and mucosal 
afferents become hypersensitive following recovery from inflammation [21,37]. Overall, these 
observations give further credence to the suggestion that effective therapies for visceral pain should 
preferentially target the higher-threshold subtypes of afferent, as these afferents display the greatest 
mechanical hypersensitivity during and after inflammation. It is now becoming apparent that certain 
ion channels have differential expression amongst these afferent subtypes, which underlies their 
overall function and their contribution to pathophysiology. 
5. TRPV1 
In peripheral afferent terminals TRPV1 acts as an immediate sensory alarm in response to low pH, 
heat and noxious agents such as capsaicin [60–62]. As such TRPV1 is probably the best know member 
of the TRP channel family, is the archetypal somatic pain sensor and one of the most heavily studied 
channels in the gut. However, compared with cutaneous afferents the role of TRPV1 in the viscera is 
not straightforward as its expression is not necessarily indicative of sensory neuron "nociceptor" 
function. Firstly, TRPV1 is also expressed in non-neuronal gut tissues, such as the oesophageal 
mucosa [63]. Secondly, all classes of low and high-threshold afferents in vagal and spinal pathways 
respond, in varying degrees, to capsaicin [33,53,64–66]. In particular, there is a high functional 
expression of TRPV1 in all colonic afferent subtypes [52,53,65,66]. In fact TRPV1 expression is 
greater in colonic innervating neurons than those innervating the skin with as many as 80% of colonic 
splanchnic colonic neurons expressing TRPV1 [52,53,65,67,68]. Thirdly, acute capsaicin application 
can subsequently decrease [49], increase [53] or have no effect on mechanosensitivity [49,64], 
depending on the class of gut afferent studied.  
Stark contrasts between somatic and visceral afferents are also apparent when investigating 
mechanosensory function in TRPV1–/– mice. Deletion of TRPV1 has no effect on somatic 
mechanosensory function [69]; however deficits are apparent in intestinal afferents, specifically certain 
types of low-threshold distension sensitive gastro-oesophageal, jejunal and pelvic colonic afferents 
(Figure 3) [51,52,70]. By contrast, high-threshold gut afferents are unaffected by TRPV1 deletion [52,70]. 
Nevertheless, TRPV1 has been strongly implicated in contributing to visceral pain. The ability of 




TRPV1 to respond to low pH [61] places it in a prime position to sense oesophageal acid reflux, giving 
rise to the sensation of heartburn, whilst intra-oesophageal capsaicin instillation induces symptoms of 
epigastric burning [71]. In animal models intra-colonic capsaicin administration causes pronounced 
visceral pain [72,73], whilst TRPV1–/– mice also display decreased visceromotor responses (VMR) to 
colorectal balloon distension (CRD) [52], suggesting an involvement of TRPV1 in signalling 
behavioural aspects of colonic pain.  
Figure 2. Specific classes of murine mechanosensitive colonic afferent become 
hypersensitive during and after inflammation. TNBS-induced colitis causes pronounced 
mechanical hypersensitivity in (A) high-threshold splanchnic (LSN): (A i) mesenteric 
afferents and (A ii) serosal afferents and (A iii) increases the percentage of afferents 
responding at a given stimulus intensity. These effects on mechanosensitivity become more 
apparent after resolution of inflammation (recovery; 30 days post-TNBS administration) 
when compared with acute conditions (7 days post-TNBS); (A iv) By contrast, pelvic (PN) 
high-threshold serosal afferents only become hypersensitivity following resolution from 
inflammation (recovery); (B) Low-threshold afferents display little or no change in 
mechanosensitivity after TNBS-induced colitis. Minor, but significant increases in mucosal 
responsiveness are observed in (B ii) mucosal and (B iii) muscular/mucosal afferents. By 
contrast, (B i) muscular and (B iii) muscular/mucosal afferent responses to stretch are 
unaffected by inflammation in the mouse. Modified from Hughes et al., [37] with 
permission. 
 
Numerous inflammatory mediators can interact with TRP channels to modulate their functional 
properties (see Table 1) [74]. TRPV1 is no exception and in colonic innervating DRG neurons 5-HT can 
sensitize TRPV1 function [75]. Specifically, 5-HT incubation increases capsaicin- and proton-evoked 
currents by 1.6- and 4.7-fold respectively. 5-HT also decreases the activation threshold temperature 
of TRPV1 from 42 to 38°C. Interestingly, these effects can be mimicked by 5-HT2 and 5-HT4 
receptor agonists. Correspondingly, this sensitisation of TRPV1 can be reduced by selective 5-HT2 and 
A) High threshold afferents
i) LSN Mesenteric ii) LSN Serosal
ii) PN Mucosali) PN Muscular iii) PN Muscular/Mucosal
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5-HT4 receptor antagonists but not by a 5-HT3 receptor antagonist [75]. Activation of another class of 
receptor, Protease Activated Receptor-2 (PAR2) can also sensitize TRPV1, increasing capsaicin 
currents over time following activation of PAR2 with a Protease Activated Receptor2-Activating 
Peptide (PAR2-AP) [76,77]. PARs also interact with other TRP channels as discussed below. 
Figure 3. Limited contribution of TRPA1, TRPV4, TRPV1 and ASIC3 to low-threshold 
afferent mechanosensitivity. TRPA1 deletion only reduces the responsiveness of (A) 
mucosal and (C) muscular/mucosal afferents to mucosal stroking and does not affect the 
stretch responses of (B) muscular or (C) muscular/mucosal afferents. Deletion of TRPV4 
has no effect at all on low threshold afferent mechanosensitivity (A–C). Deletion of 
TRPV1 or ASIC3 markedly reduces the stretch response of (C) muscular/mucosal afferents. 
However,TRPV1 or ASIC3 deletion has no effect on mucosal or muscular afferent 
mechanosensitivity (A, B). TRPV4 modified from Brierley et al., [36] with permission. 
TRPA1 modified from Brierley et al., [35] with permission. TRPV1 and ASIC3 modified 
from Jones et al., [52] with permission. 
 








































































































































































































































































































































































































































































































































































Table 1. Summarizes the ion channels implicated in signaling gut based “physiological” 
pain in healthy conditions and details where (gut innervating neurons, gut innervating 
afferents or whole animal gut based recordings) this function was demonstrated. This table 
also documents interactions of these channels with inflammatory mediators, specifically 
those identified within gut neurons or gut afferents. √: Indicates a demonstrated role for 
this channel in gut neurons, gut afferents or whole animal gut based recordings; X: 
Indicates no demonstrated role for this channel; ND: indicates the function of this channel 
has not been determined in the setting specified; ↑ indicates the inflammatory mediator 
increases channel function; ↓ indicates the inflammatory mediator decreases channel 
function; ↔ indicates the inflammatory mediator has no effect on channel function. 
Functional role for 







Is channel function in gut neurons 
altered by inflammatory mediators? 
TRPV1 √ √ √ √; 5-HT ↑, PAR2 ↑ 
TRPV4 √ √ √ √; 5-HT ↑, PAR2 ↑,  Histamine ↑, PAR4 ↓ 
TRPA1 √ √ √ √; Bradykinin ↑, 4-HNE ↑, PAR2  ↔ or ↑ 
ASIC1 ND √ √ ND 
ASIC2 ND √ √ ND 
ASIC3 ND √ √ ND 
NaV1.5 X ND ND ND 
NaV1.7 √ ND ND ND 
NaV1.8 √ ND √ √; TNFα ↑ 
NaV1.9 √ ND X ND 
Kv √ ND ND √; TNFα ↓ 
5.1. TRPV1: Contribution to Inflammation 
A perhaps somewhat overlooked function of TRPV1 activation is its ability to cause neurogenic 
inflammation, via local release of substance P and CGRP. Mice lacking TRPV1 develop significantly 
less oesophagitis after acid exposure compared with TRPV1+/+ mice [78], whilst administration of a 
TRPV1 antagonist before or after intracolonic TNBS administration significantly reduces colitis 
severity [79,80]. Similarly, in rats and mice TRPV1 antagonists attenuate disease severity in dextran 
sulphate sodium (DSS)-induced colitis [81,82]. However, diametrically opposed to these observations 
there are also reports of TRPV1 having a protective role in inflammatory models, with TRPV1 
activation improving DSS-induced colitis in mice [83]. Furthermore, a dinitrobenzene sulfonic acid 
model causes more severe colitis in TRPV1–/– mice than TRPV1+/+ mice [84]. 
5.2. TRPV1: Contribution to Visceral Hyperalgesia  
In addition to contributing to inflammation TRPV1 also mediates the development and short term 
maintenance of colonic hypersensitivity in non-inflammatory and neonatal models [85–87]. However, 
the role of TRPV1 in colonic sensory afferents after the initial insult remains somewhat unclear and 
appears to depend on the model and indeed the exact time frame studied. In adult inflammatory models 
there appears to be a transient role for TRPV1, with initial increases in TRPV1 expression and function 
during the height of active colonic inflammation [57,80,88,89], which return to normal at later time 




points [80]. Paradoxically, visceral mechanical hypersensitivity still remains at this and longer time 
points [21,37,90,91]. Furthermore, TRPV1 deletion or the use of TRPV1 antagonists only partially 
reverses mechanical hypersensitivity and hyperalgesia [80,86] (Figure 5), indicating the involvement of 
other channels in colonic afferent hypersensitivity. Clearly some controversy exists and resolution is 
clouded due to species differences, the different hypersensitivity models used and also the time points at 
which studies take place. Identifying a clear contribution for TRPV1 in afferent hypersensitivity is further 
complicated by its ability to act as a polymodal sensor and its contribution to the inflammatory process.  
Figure 4. Significant contribution of TRPA1 and TRPV4 to normal colonic high-threshold 
afferent mechanosensory function. Deletion of TRPA1 or TRPV4 markedly reduces the 
mechanosensitivity of high-threshold colonic splanchnic (A) mesenteric and (B) serosal 
afferents. Deletion of ASIC3 also reduces afferent mechanosensitivity, but the effects are 
more modest (A, B). In stark contrast, ASIC1a and ASIC2 deletion either increases 
mechanosensitivity or causes no effect (A, B), indicating at best a modulatory role for these 
channels. Overall, by far the greatest deficits are apparent in the TRPV4–/– and TRPA1–/– 
afferents. TRPV4 modified from Brierley et al., [36] with permission. TRPA1 modified 
from Brierley et al. [35] with permission. ASIC1a, ASIC2, ASIC3 modified from  
Page et al. [115] with permission. 
 
5.3. TRPV1: Therapeutic potential? 
Perhaps the best indicator for TRPV1s involvement in gut based pain comes from human patient 
studies which indicate increased expression or function of TRPV1 in Gastro-Oesoghageal Reflux 
Disease, Functional Dyspepsia, Inflammatory Bowel Disease and Irritable Bowel Syndrome (Table 2). 
The number of TRPV1 expressing fibres are increased in biopsies from patients with erosive reflux [92] 
and non-erosive reflux disease [93], whilst TRPV1 gene expression is increased in the oesophageal 
mucosa of both patient groups [94]. Functional Dyspepsia patients are hypersensitive to a capsaicin 
challenge [95–96], whilst a TRPV1 G315C polymorphism increases the susceptibility of developing 
Functional Dyspepsia [97]. Further down the gut, TRPV1 immunoreactive colonic nerve fibres are 
increased in patients with active Inflammatory Bowel Disease [98]. Studies of biopsies from patients 
 














































































































































































































































































































































































































































































with Irritable Bowel Syndrome show that mucosal fibres containing TRPV1 are increased and that this 
increase may correlate with symptoms [99]. Furthermore, patients with idiopathic rectal hypersensitivity 
have increased TRPV1 fibres in all layers of the gut wall [100]. 
Table 2. Summarizes the ion channels implicated in signaling gut based “inflammatory” or 
“chronic” pain and details where (gut innervating neurons, gut innervating afferents or 
whole animal gut based recordings) this function was demonstrated. This table also 
documents which channels have altered expression in gut based human pain syndromes.  
√: Indicates a demonstrated role for this channel in gut neurons, gut afferents or whole 
animal gut based recordings; X: Indicates no demonstrated role for this channel;  
ND: indicates the function of this channel has not been determined in the setting specified. 
Altered channel function 








Is channel expression or 
function altered in gut 
based human diseases? 
TRPV1 √ √ √ √ 
TRPV4 √ √ √ √ 
TRPA1 ND √ √ ND 
ASIC1 ND ND ND ND 
ASIC2 ND ND ND ND 
ASIC3 ND √ √ √ 
NaV1.5 ND ND ND √ 
NaV1.7 X ND ND √ 
NaV1.8 √ ND √ ND 
NaV1.9 X ND √ ND 
Kv √ ND ND ND 
Although TRPV1 may appear the perfect target for pharmacotherapy these findings should be taken 
with a caveat. Most of these studies are conducted using human mucosal biopsies and the fibres 
innervating the mucosa are the least likely, at least in normal conditions, to signal pain due to their 
very low activation thresholds to mechanical stimuli. In addition to increased TRPV1 expression some 
studies have also reported that the density of neural innervation is also increased in patient biopsies. In 
particular significant increases in total nerve fibre counts, as indicated by PGP9.5 and substance P-
immunoreactive fibres [99], is suggestive of axonal sprouting. As elegantly noted previously by Holzer 
the benefit of TRPV1 therapy may pivot around whether “TRPV1 up-regulation in gut disorders 
reflects a causal implication rather than just a marker of enhanced sensitivity and functionality of 
afferent neurons or enhanced arborisation of their fibres in the periphery” [101]. If the former is true, 
then it will be a tricky path to follow, as many different types of gut afferent express TRPV1. 
Therefore blocking TRPV1 may help with pain relief; however, it may also concurrently perturb 
normal physiology. These factors combined with the well documented complications of hyperthermic 
responses in clinical trials involving TRPV1 antagonists [102] raise a cautionary tale. Nevertheless, a 
recent study suggests targeting specific modalities of TRPV1 activation may overcome the 
hyperthermic response in animal models [103]. Additionally, TRPV1s involvement in neurogenic 
inflammation may suggest a “window of opportunity” whereby a TRPV1 antagonist may be beneficial 




in reducing the initial inflammatory response and preventing subsequent inflammation-induced 
changes in ion channel expression within gut sensory afferent neurons. Another possibility would be to 
target specific TRPV1 splice variants. For example, in the rat oesophageal epithelium there is a report 
of a TRPV1 splice variant which is significantly different (60 kDa vs. 95 kDa) to the sensory DRG 
form of TRPV1 [63]. Depending on the functionality of the 60 kDa protein, one could suggest it as a 
specific therapeutic target for the "first step" in acid detection in the oesophageal mucosa and therefore 
the subsequent acid reflux associated pain without the potential hyperthermic side-effects. Although 
this may treat the pain associated with reflux it would not address the underlying cause [104–106]. 
6. TRPA1 
TRPA1 has been implicated as a mechanosor [107] and has recently emerged as a major mediator of 
inflammatory pain [108]. In gut innervating sensory neurons TRPA1 expression is more restricted than 
that observed for TRPV1. In these neurons TRPA1 is localised in both vagal and spinal afferents with 55% 
of vagal gastro-oesophageal afferent neurons, 54% of splanchnic colonic and 58% of pelvic colonic 
innervating DRG neurons expressing TRPA1 [35,109]. In peripheral tissue, TRPA1 is located in 
mucosal, serosal and mesenteric nerve fibres [35] indicating TRPA1 is well placed to participate in the 
function of these afferent subtypes. Correspondingly, TRPA1 agonists (mustard oil or cinnamaldehyde) 
universally evoke mechanical sensitisation of serosal and mesenteric [35] high-threshold [53] colonic 
afferents and pelvic mucosal afferents [35]. These compounds also activate colonic innervating DRG 
neurons in isolation [109]. The use of TRPA1–/– mice has allowed specific determination of the 
afferent fibres types which utilize TRPA1 to detect mechanical stimuli. These studies show striking 
deficits occur in high-threshold colonic afferents, specifically splanchnic mesenteric afferents and 
splanchnic and pelvic serosal afferents (Figure 4) [35]. Furthermore, TRPA1 makes a modest 
contribution to low-threshold mucosal afferent mechanosensitivity in both vagal and pelvic pathways 
innervating the oesophagus/stomach and colon respectively. In contrast TRPA1 does not contribute to 
the mechanosensitivity of vagal tension receptors or pelvic muscular and muscular/mucosal afferents 
(Figure 3). Interestingly, these are the classes of afferent which are affected by TRPV1 deletion [51,52]. 
Another important finding is the observation that TRPA1 deletion increases the activation thresholds of 
serosal and mesenteric afferents to mechanical stimuli [35], suggesting TRPA1 is important in setting 
mechanical activation thresholds. The predominant mechanosensory role for TRPA1 in high-threshold 
serosal and mesenteric afferents combined with the ability of TRPA1 agonists to increase the mechanical 
responsiveness of these afferents is suggestive of an involvement in pain. Supporting this assertion 
TRPA1–/– mice also display decreased VMR to high intensity (80 mmHg) CRD [35], but not at lower 
distension pressures (15–60 mmHg) [109]. The observation that intra-colonic administration of TRPA1 
agonists enhances VMR to the higher distending pressures (45 and 60 mmHg) within 2 hours of 
administration [109] suggests TRPA1 can modulate visceral mechanical hyperalgesia (discussed below). 
Further inference can also be deduced by the observation that the classes of TRPA1–/– afferent displaying 
deficits are exactly the same classes of TRPA1+/+ afferent displaying mechanical hypersensitivity after 
TNBS induced colitis, namely splanchnic mesenteric and serosal afferents and pelvic serosal and 
mucosal afferents (compare Figures 2,3 and 4) [21,35,37].  




6.1. TRPA1: Contribution to Inflammation 
Mustard oil has long been used as a visceral inflammatory model to provoke tissue damage and sensitize 
nociceptors [73,110]. We now know that mustard oil (allyl-isothiocynate) is a TRPA1 agonist [111] and 
recent findings provide us with a more complete understanding of how this compound causes these 
effects in the viscera. TRPA1 agonists induce neurogenic inflammation via the release of substance P 
and CGRP [112] with increases in cytokines associated with macrophage and neutrophil activation and 
recruitment [113]. However, the contribution of TRPA1 to different types of inflammation may not be 
as prevalent as that of TRPV1, with recent reports suggesting the severity of colitis induced by TNBS 
is unaffected by TRPA1 deletion [109]. 
6.2. TRPA1: Contribution to visceral hyperalgesia.  
TRPA1 is also directly activated by irritants such as the endogenous aldehyde, 4-Hydroxynonenal 
(4-HNE) [74,108,112]. Intracolonic administration of mustard oil or 4-HNE increases the VMR to 
CRD at the highest distending pressures (45 and 60 mmHg, respectively) within 2–3 hours. 
Correspondingly, these agonists also cause neuronal activation, as indicated by induced c-fos 
expression, in the superficial laminae (I and II) of thoracolumbar (splanchnic) and lumbosacral (pelvic) 
spinal cord in TRPA1+/+ but not TRPA1–/– mice [109]. Thus intra-colonic administration of TRPA1 
agonists activates spinal nociceptors and causes visceral hyperalgesia. TRPA1 is also indirectly 
activated by inflammatory mediators such as bradykinin and PARs [74,108,112]. TRPA1 mediates 
bradykinin-induced mechanical hypersensitivity in the guinea-pig oesophagus [114] and the 
bradykinin-induced mechanical hypersensitivity observed in splanchnic serosal afferents [35,48]. 
TRPA1 is also required for PAR2-induced visceral hyperalgesia [109] as the delayed visceral 
mechanical hypersensitivity to CRD caused by intracolonic administration of the PAR2-AP in 
TRPA1+/+ mice is completely absent in TRPA1–/– mice. Although minor controversy exists because in 
splanchnic colonic serosal afferents the association between PAR2 and TRPV4 seems to predominate 
over PAR2/TRPA1 interactions [35] and may be related to the promiscuity of PAR2 interactions on 
numerous TRP channels (discussed below). 
In addition to short term sensitisation, TRPA1 also has a consistent and longer term role in visceral 
hyperalgesia. TRPA1 agonists cause greater mechanical hypersensitivity in afferents from animals 
with acute TNBS-induced colitis compared with untreated mice, indicating an enhanced role for 
TRPA1 during inflammation [35]. In the whole animal, at 3 days post-TNBS administration, visceral 
hypersensitivity and increased neuronal c-fos expression in the spinal cord normally observed in 
TRPA1+/+ mice are completely absent in TRPA1–/– mice (Figure 5) [109]. Furthermore, intrathecal 
injection of an antisense oligodeoxynucleotide, to down regulate TRPA1 expression, suppresses the 
colitis-induced hyperalgesia to nociceptive CRD and intracolonic mustard oil in rats studied 8 days 
post-TNBS [89]. 




Figure 5. Multiple ion channels contribute to short and long term visceral hyperalgesia.  
(A) TRPA1 deletion reduces the mechanical hyperalgesia induced by TNBS colitis;  
(B) Mechanical hyperalgesia evoked by intra-colonic PAR2-AP administration in (B i) 
TRPV4+/+ mice is lost in ii) TRPV4–/– mice; (C) Administration of a TRPV1 antagonist 
(JYL1421) after the induction of colitis with TNBS reduces mechanical hyperalgesia;  
(D) Deletion of NaV1.8 reduces both (D i) capsaicin and (D ii) mustard oil induced colonic 
hyperalgesia; (D iii) NaV1.8–/– DRG neurons innervating the jejunum do not display the 
hyper-excitability induced by Nippostrongylus brasiliensis infection; (D iv) By contrast, 
NaV1.9–/– neurons still display Nippostrongylus brasiliensis induced hyper-excitability; (E) 
KV IA and IK currents are reduced in colonic innervating DRG neurons (E i) 10 days post-
Citrobacter rodentium infection, whilst (E ii) KV IA currents are also reduced 30 days post-
infection. (A) modified from Cattaruzza et al. [109], used with permission from The 
American Physiological Society; (B) modified from Sipe et al. [124] used with permission 
from The American Physiological Society; (C) modified from Miranda et al. [80] with 
permission; (D) i-ii) modified from Laird et al. [73] with permission. (D iii-iv) modified 






E) KV channels: IA and IK currents
i) Intra-colonic capsaicin
D) NaV1.8
ii) Intra-colonic mustard oil
i) 10 days post-infection ii) 30 days post-infection
iii) NaV1.8-/-: No hyper-excitability iv) NaV1.9-/-: Hyper-excitability
B) TRPV4 C) TRPV1
i) TRPV4+/+ ii) TRPV4-/-




6.3. TRPA1: Therapeutic potential? 
Since intense focus to determine the role of TRPA1 has occurred only relatively recently there is a 
lack of studies to indicate whether or not its expression is altered in organic and functional bowel 
disorders. However, given the results documented from animal models it appears an extremely good 
candidate to target for the treatment of visceral pain. Although there is a mild contribution of TRPA1 
to low-threshold afferents, its major contribution appears to occur in the high-threshold classes of 
afferent, their sensitisation by various mediators and the development of hyperalgesia. The 
contribution of TRPA1 to mucosal afferent mechanosensitivity may be beneficial in diarrhoea 
disorders such as diarrhoeal predominant IBS and Inflammatory Bowel Disease, since mucosal 
afferents are likely to play a role in initiating propulsive motility. There is also emerging evidence for 
involvement of TRPA1 in mediator release from enterochromaffin and enteroendocrine cells [116–118] 
and this function needs to be considered. Although a role for TRPA1 in hearing mechanotransduction 
was a major focus, this is less likely based on recent data [119,120] and potential therapeutic 
opportunities in pain may still be problematic due to a modulatory role for TRPA1 in most classes of 
somatic afferents [121,122]. Most recently a gain-of-function mutation in TRPA1 has been shown to 
cause Familial Episodic Pain Syndrome [123]. 
7. TRPV4 
In gut innervating sensory DRG neurons TRPV4 expression is even more restricted than that 
observed for TRPA1. TRPV4 is localised in 38% of gastro-oesophageal vagal neurons [36], 65–76% 
of splanchnic colonic DRG neurons [36,124] and 58% of pelvic colonic DRG neurons [36]. Although 
TRPV4 expression is more restricted it is actually enriched within colonic DRG neurons, with its 
expression 20-fold greater in splanchnic colonic DRG neurons than in whole DRG. In the periphery 
TRPV4 protein co-localizes with CGRP in colonic nerve fibres in the serosal and mesenteric 
attachment. By contrast, TRPV4 expression is scarce in intramuscular or mucosal nerve fibres [36]. 
Consistent with the lack of TRPV4 expression in gastro-oesophageal vagal neurons deletion of 
TRPV4 has absolutely no effect on vagal afferent function [36]. However, in colonic afferents, where 
TRPV4 is enriched, mechanosensory responses are dramatically reduced in TRPV4–/– mice. This is the 
case for both splanchnic serosal and mesenteric afferents (Figure 4). TRPV4 deletion also increases the 
mechanosensory thresholds of these afferents suggesting TRPV4, like TRPA1, contributes to setting 
mechanical activation thresholds. Furthermore, pelvic serosal afferents display similar deficits in 
mechanosensory responses and thresholds to those seen in the splanchnic pathway. As was the case in 
the vagal pathway low-threshold pelvic afferents are completely unaffected by TRPV4 deletion (Figure 3). 
Taken together this data indicates TRPV4 makes a specific and major contribution to high-threshold 
colonic afferent mechanosensory function. The extent of these deficits in mechanosensitivity are some 
of the largest reported in any afferent population, somatic or visceral [36]. These changes in colonic 
neuron function also translate to decreased VMR to CRD in TRPV4–/– mice or in mice with down-
regulated TRPV4 expression (via siRNA intrathecal injection), the extent of which is particularly 
apparent at higher distension pressures [36,124,125]. 




7.1. TRPV4: Contribution to visceral hyperalgesia.  
The endogenous TRPV4 agonist 5,6-EET (an arachidonic acid metabolite) significantly potentiates 
mechanosensory responses in TRPV4+/+ mice, which is lost in TRPV4–/– mice. Another TRPV4 agonist, 
4α-PDD causes significant TRPV4 mediated calcium influx in isolated colonic DRG neurons [125]. 
Intracolonic administration of 4α-PDD in TRPV4+/+ mice increases neuronal c-fos expression in the 
lumbosacral spinal cord and causes dose-dependent visceral hypersensitivity [125]. Therefore, TRPV4’s 
role is not only linked to visceral mechanosensation but also to visceral hypersensitivity [36,124,125].  
TRPV4 can be sensitised by a series of inflammatory mediators both in vivo and in vitro. Pre-
exposure of colonic DRG neurons to histamine or 5-HT, increased Ca2+ responses induced by 4αPDD 
via various second messenger pathways [126]. 5-HT or histamine also enhances TRPV4 expression at 
the plasma membrane. Down-regulation of TRPV4, via siRNA intrathecal injection significantly 
reduces the hypersensitivity induced by 5-HT or histamine [126]. Although PAR2 interacts with 
TRPV1 and TRPA1 (see above) there is evidence for a strong interaction with TRPV4, which 
underlies visceral hypersensitivity [124,125]. TRPV4 and PAR2 are anatomically and functionally co-
expressed in a large percentage of colonic innervating neurons [124,125]. In isolated colonic DRG 
neurons the PAR2-activating peptide, PAR2-AP, sensitizes TRPV4 mediated currents, whilst the PAR2-
AP also activates splanchnic serosal colonic afferent fibres by a TRPV4-dependent mechanism [124]. 
Intra-colonic administration of PAR2-AP also causes enhanced VMR to CRD at higher distending 
pressures (>40 mmHg) measured 6 hours [124,125] and 24 hours [124] after administration. This is not 
observed in TRPV4–/– mice at either time point [124,125], suggesting TRPV4 mediates both the acute 
and delayed hyperalgesia induced by PAR2 activation [124] (Figure 5). Taken together this data 
suggests TRPV4 is a common mechanism to several known mediators of visceral hypersensitivity, 
including, histamine, 5-HT and PAR2. Conversely, a related protease activated receptor, PAR4 is actually 
responsible for suppressing the excitability of colonic DRG neurons [127] whilst intracolonic PAR4 
agonist administration significantly reduces PAR2 and TRPV4 agonist-induced allodynia and 
hyperalgesia in response to CRD [128]. 
7.2. TRPV4: Therapeutic potential? 
At face value TRPV4 appears to be an ideal target for the treatment of visceral pain. TRPV4 has a 
high specificity for high-threshold spinal colonic afferents with one of the largest deficits in 
mechanosensory function documented in null mutant mice. There appears to be little to no role in low-
threshold spinal afferents or in vagal afferent fibres. TRPV4 is concentrated in the outer layers of the 
colon and is association with blood vessels, in particular during active inflammation of the colon 
associated with Crohn’s disease and Ulcerative Colitis [36]. Furthermore, serine proteases levels 
[129,130], 5-HT signalling [131] and histamine [24–26] are all known to be increased in IBS patients 
and TRPV4 interacts with these mediators. However, unlike TRPV1 and TRPA1 currently there are no 
antagonists available for TRPV4. In terms of non-gut actions, TRPV4 contributes to the detection of 
osmotic stimuli [134–136] and also to somatic inflammatory pain [137–141]. 




8. Acid Sensing Ion Channels 
ASICs are members of the DEG/ENaC family of ion channels which contribute to the detection of pH 
and mechanical stimuli. ASIC1, 2, and 3 mRNA expression has been detected in vagal and spinal 
pathways but their abundance varies greatly between gut innervating afferents [142,143]. ASIC1 has a 
greater expression in gastro-oesophageal innervating nodose ganglion neurons compared with colonic 
innervating neurons, similar levels of ASIC2 are in both sets of neurons [142,143], whilst colonic 
neurons contain more ASIC3 than gastro-oesophageal neurons [142,143]. Indeed as little as 30% of 
colonic neurons express ASIC1, whilst 47% express ASIC2 and 73% express ASIC3 [142,143]. 
Correspondingly, studies utilizing ASIC–/– mice have demonstrated widespread differences in the 
mechanosensory mechanisms between different pathways. Deletion of ASIC1a increases the mechanical 
sensitivity of splanchnic colonic and vagal gastro-oesophageal afferents (Figure 4) [115,144]. Disruption 
of ASIC2 has varied effects: increasing mechanosensitivity in gastro-oesophageal mucosal endings, 
decreasing gastro-oesophageal tension receptors, increasing colonic serosal endings, and causing no 
change in colonic mesenteric endings (Figure 4) [115]. In ASIC3–/– mice, gastro-oesophageal tension 
afferents have markedly reduced mechanosensitivity, whilst mucosal afferents are unchanged. In the 
colon splanchnic serosal and mesenteric afferents display mechanosensory deficits (Figure 4) [115], 
whilst in the pelvic nerve muscular/mucosal afferents have significantly reduced mechanosensory 
responses (Figure 3) [52]. Low-threshold pelvic mucosal and muscular afferents remained unchanged 
(Figure 3) [52]. Although the deficits in mechanosensitivity observed in the respective ASIC–/– mice are 
fairly modest (Figure 3 and 4), particularly compared with those documented for TRPV4 and TRPA1, the 
effects on afferent mechanosensitivity translate to changes in the whole animal. Observations of altered 
gastric emptying and faecal output are found in ASIC1a–/– and ASIC2–/– mice respectively [115,144], 
whilst reductions in colonic mechanosensory function in ASIC3–/– mice [52,115] translate to 
significantly reduced VMR to CRD [52]. Differences between the upper gut and lower gut afferents are 
also apparent in the sensitivity to the non-selective DEG/ENaC blocker benzamil. Splanchnic colonic 
afferent mechanosensitivity is virtually abolished by benzamil application, whereas gastro-oesophageal 
afferents are only marginally inhibited. Deletion of ASIC2 or ASIC3 significantly reduces the ability of 
benzamil to reduce splanchnic serosal afferent mechanosensitivity, whilst deletion of ASIC1a has no 
effect on benzamil sensitivity [143]. ASIC3 also contributes to visceral peripheral sensitization as 
demonstrated by an intra-colonic zymosan induced increase in VMR in control mice which is lost in 
ASIC3–/– mice [86]. Deletion of ASIC3 also prevents gastritis-induced acid hyper-responsiveness of the 
stomach-brainstem axis [145]. 
8.1. ASICs: Therapeutic Potential? 
ASICs form heteromultimers [146,147] and the composition of these heteromultimers differs depending 
on the tissue studied [18]. This is reflected in benzamil having a greater effect on colonic afferents than 
vagal afferents and the predominant expression of ASIC3 in splanchnic colonic neurons and ASIC1 
transcripts in gastro-oesophageal afferents [143]. In the gut only ASIC3 makes a positive contribution to 
mechanosensitivity, a conclusion that is emphasized by its key role in colonic peripheral sensitization. In 
humans increased ASIC3 expression is observed in Crohn's disease intestine [148]. Therefore, targeting 




specific heteromultimers, those which heavily express ASIC3, could be beneficial, although the role of 
ASIC3 in vagal and somatic mechanoreceptors has to be taken into consideration. Potent ASIC3 blockers 
are becoming available [149,150] which is promising, however, they need to be extremely selective given 
that ASIC1a and ASIC2 are involved in CNS and baroreceptor function [151,152]. 
9. Voltage Gated Sodium and Potassium Channels (NaV and KV) 
These channels are critical in determining the excitability of sensory neurons, with Voltage Gated 
Sodium Channels (NaV) mediating the rapid upstroke of the action potential, whilst Voltage Gated 
Potassium Channels (KV) act to repolarise the cell membrane, limiting repetitive firing. NaV channels 
have distinct electrophysiological and pharmacological properties. This review will focus on NaV1.7, 
NaV1.8 and NaV1.9, for detailed reviews see [16,153–156]. NaV1.7 mediates a Tetrodotoxin (TTX)-
sensitive current important in setting action potential generation threshold. NaV1.8 is a TTX-resistant 
current contributing to the upstroke of action potentials and to continuous firing activity during 
prolonged depolarisations. NaV1.9 mediates a persistent current that contributes to setting resting 
membrane potential [155]. In the gut, colonic innervating thoracolumbar DRG neurons contain 
transcripts for NaV1.7, NaV1.8 and NaV1.9 [157] although functionally most exhibit NaV1.8 and NaV1.7 
like currents with few exhibiting currents similar to those mediated by NaV1.9 [158]. Voltage-gated 
Potassium channels (KV) comprise various subunits [159] and physiologically are broadly classed on 
their inactivation kinetics as either delayed rectifier (IK) currents or transient outward (IA) currents [16].  
9.1. NaV and KV: Contribution to Visceral Hyperalgesia. 
It is clear from most studies utilizing inflammatory, nematode or bacterial models that gut 
innervating neurons become hyper-excitable after the initial insult. This is apparent in neurons 
innervating the stomach [160–163], small intestine [132,164–166] and the colon [133,157,158]. As 
such these changes are consistent across different regions of gut and across different experimental 
models. This hyper-excitability is characterized by a decreased threshold for activation, increased 
firing rate and changes in NaV and KV channels. Specifically, these changes relate to an increase in 
TTX-resistant NaV channel function and suppression of IA and IK currents. Recent reports indicate a 
crucial role for NaV1.8 in colonic innervating DRG neurons and that its expression is differentially 
regulated across varying time points during colitis [157]. Furthermore, nematode induced jejunal 
neuronal hyperexcitability is lost in NaV1.8–/– mice but not NaV1.9–/– mice (Figure 5) [132]. 
Correspondingly, at the level of the whole animal, NaV1.8–/– mice show blunted pain and hyperalgesia 
responses to intra-colonic capsaicin (TRPV1 agonist) or mustard oil (TRPA1 agonist) (Figure 5) [73]. 
Although NaV1.9–/– mice display normal acute pain responses they display reduced inflammation-
induced visceral hyperalgesia [167]. In terms of KV, IA and IK currents are reduced in colonic 
innervating DRG neurons 10 days post-Citrobacter rodentium infection, whilst suppression of KV IA 
currents contributes to neuronal hyper-excitability 30 days post-infection (Figure 5) [133]. 
Most recently it has been shown that the pro-inflammatory cytokine Tumour Necrosis Factor-α 
(TNFα) enhances NaV1.8 currents and suppresses IA and IK currents to evoke hyper-excitability in 
colonic DRG neurons (Figure 6).  




Figure 6. Supernatants from visceral pain patients alter visceral afferent function. (A) (A i) 
Mucosal supernatants obtained from colonic mucosal biopsies of IBS patients increase the 
nerve discharge of rat jejunal afferents compared with healthy controls (HC) or saline alone; 
(A ii) When tested on isolated DRG neurons the IBS supernatant-induced increases in 
intracellular Ca2+ were significantly higher than those obtained with supernatants from 
healthy control (HC) patients. Modified from Barbara et al. [26] with permission; (B) (B i) 
Peripheral blood mononuclear cell (PBMC) supernatants from post-infectious diarrhoea-
predominant Irritable Bowel Syndrome (PI-IBS) patients cause a marked increase in the 
mechanosensory response of mouse pelvic colonic serosal afferents; (B ii) Original record on 
the mechanosensory response of a pelvic serosal afferent before and after PI-IBS 
supernatants. Modified from Hughes et al. [168] with permission; (C) Supernatants obtained 
from colonic biopsies from Ulcerative Colitis (UC) patients cause significant decreases in 
colonic DRG neuron (C i) KV IA currents and (C ii) IK currents compared with control 
supernatant. Modified from Ibeakanma and Vanner [169] with permission. 
 
 
These TNFα induced effects on NaV and KV currents are similar to those observed during TNBS-
induced colitis [169]. Colonic biopsies from Ulcerative Colitis patients contain increased levels of 
TNFα. Correspondingly, supernatants from these biopsies also caused neuronal hyperexcitability via 
enhancement of NaV1.8 currents and suppression of KV IA and IK currents. Similarly, mucosal 
supernatants obtained from the colonic mucosal biopsies of IBS patients increase nerve discharge of 
rat jejunal afferents and cause greater supernatant-induced increases in intracellular Ca2+ compared 
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with those from healthy control patients (Figure 6) [26]. Furthermore, it has also been demonstrated 
that peripheral blood mononuclear cells from post-infectious diarrhoea-predominant IBS patients also 
have elevated cytokine levels [27] and supernatants from these cells cause mechanical hypersensitivity 
in splanchnic and pelvic colonic afferents (Figure 6) [168]. 
9.2. NaV and KV: Therapeutic potential? 
Although NaV1.8 is an obvious choice as it appears to play a crucial role in visceral hyper-
excitability in animal models, as yet there are no documented reports of altered function or expression 
in gut pain syndromes. However, other NaVs have been implicated for example IBS patients with 
mutations in SCN5A (the gene encoding NaV1.5) are more likely to report gastrointestinal symptoms, 
especially abdominal pain [170]. A NaV1.7 gain-of-function mutation in SCN9A, is linked to the 
human condition “familial rectal pain syndrome” now renamed “paroxysmal extreme pain disorder”. 
As the name suggests it is characterised by rectal and abdominal pain commonly associated with 
defecation [171–173]. However, there is a lack of data to indicate which afferents are actually 
associated with this condition and paradoxically the hypersensitivity in colonic DRG neurons in animal 
inflammatory models appears to involve NaV1.8 and not NaV1.7 [157,158]. Furthermore in another 
condition, idiopathic rectal hypersensitivity, colonic specimens display more nerve fibres expressing 
NaV1.7 [174]. Although intra-rectal lidocaine administration has been shown to reduce abdominal pain 
associated with diarrhoea-predominant IBS [175] knowing which NaV to target in gut pain syndromes 
remains a difficult question. Therefore targeting mediators, such as TNFα, which interact with these 
channels may be a therapeutic option, particularly in Ulcerative Colitis patients [169] and post-
infectious diarrhoea-predominant IBS patients [27,168]. The specific identity of the KV subunits 
implicated in the inflammation induced suppression of IA and IK currents remains unreported. 
In terms of somatic systems NaV1.8 is highly expressed in cutaneous nociceptors [176,177] and 
NaV1.7, NaV1.8 and NaV1.9 are all implicated in somatic pain, but again it depends on the model used. 
Neuropathic pain develops normally in mice lacking both NaV1.7 and NaV1.8 [178], however NaV1.7, 
NaV1.8 and NaV1.9 are critical in inflammation associated pain [179–182]. In another human disorder, 
loss-of-function SCN9A (NaV1.7) mutations cause a complete insensitivity to pain [183]. 
10. Concluding Remarks 
Despite the apparent controversy concerning what constitutes a gut innervating nociceptor it is 
becoming clear from the literature that a variety of ion channels contribute to signalling visceral pain 
and hyperalgesia in a variety of conditions. Unique combinations of channels are expressed on high-
threshold gut afferents and this may provide potential new pharmacological strategies for the 
management of pain and hyperalgesia originating from the gastrointestinal tract. To turn this potential 
into reality we must determine if promising targets from animal models translate into altered channel 
expression and function in human visceral pain disorders, whilst determining unequivocally that these 
changes are the underlying basis of visceral hyperalgesia.  
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